SPRUCE BIOSCIENCES, INC. financial data

Symbol
SPRB on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 09 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 273% % -39%
Debt-to-equity 59% % 83%
Return On Equity -204% % -98%
Return On Assets -128% % -65%
Operating Margin -7100% % -1066%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,372,043 shares -97%
Common Stock, Shares, Outstanding 1,372,043 shares 144%
Entity Public Float $2,800,000 USD -85%
Common Stock, Value, Issued $0 USD
Weighted Average Number of Shares Outstanding, Basic 766,598 shares 39%
Weighted Average Number of Shares Outstanding, Diluted 766,598 shares 39%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD -100%
Research and Development Expense $19,522,000 USD -58%
General and Administrative Expense $16,991,000 USD 16%
Operating Income (Loss) $36,513,000 USD 35%
Net Income (Loss) Attributable to Parent $38,966,000 USD 27%
Earnings Per Share, Basic -50.83 USD/shares 47%
Earnings Per Share, Diluted -50.83 USD/shares 47%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $48,906,000 USD 26%
Cash, Cash Equivalents, and Short-term Investments $48,900,000 USD 26%
Other Assets, Current $2,853,000 USD 25%
Assets, Current $52,112,000 USD 18%
Other Assets, Noncurrent $243,000 USD 252%
Assets $53,021,000 USD 17%
Accounts Payable, Current $943,000 USD -27%
Accrued Liabilities, Current $9,143,000 USD -26%
Liabilities, Current $10,086,000 USD -34%
Operating Lease, Liability, Noncurrent $419,000 USD -43%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $10,505,000 USD -36%
Retained Earnings (Accumulated Deficit) $289,234,000 USD -16%
Stockholders' Equity Attributable to Parent $42,516,000 USD 48%
Liabilities and Equity $53,021,000 USD 17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $12,727,000 USD 15%
Net Cash Provided by (Used in) Financing Activities $411,000 USD -81%
Net Cash Provided by (Used in) Investing Activities $0 USD -100%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 1,372,043 shares 144%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48,942,000 USD 26%
Deferred Tax Assets, Valuation Allowance $70,777,000 USD -17%
Deferred Tax Assets, Gross $70,954,000 USD -17%
Operating Lease, Liability $736,000 USD -28%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $53,036,000 USD -12%
Lessee, Operating Lease, Liability, to be Paid $805,000 USD -31%
Operating Lease, Liability, Current $317,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year Two $376,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $365,000 USD 3.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $69,000 USD -51%
Lessee, Operating Lease, Liability, to be Paid, Year Three $64,000 USD -83%
Deferred Tax Assets, Operating Loss Carryforwards $44,720,000 USD 26%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $775,000 USD -82%
Lessee, Operating Lease, Liability, to be Paid, Year Four $64,000 USD -83%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $177,000 USD -10%
Share-based Payment Arrangement, Expense $2,574,000 USD -52%
Interest Expense $90,000 USD -71%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%